Loading
Recursion Pharmaceuticals
Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.
Overview
Recursion Pharmaceuticals, based in Salt Lake City and listed as RXRX, is an AI-first biotechnology company that merged with Exscientia in 2024, with a clinical oncology pipeline including an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis. Its programmes include REC-1245, the RBM39 degrader in phase 1/2, REC-4881, a MEK1/2 inhibitor in phase 2 for FAP with FDA registrational discussions, and candidates against LSD1, CDK7, PI3K-alpha H1047R, MALT1 and ENPP1, and it reported revenue shortfalls alongside pipeline progress in the first quarter of 2026. OnCo links it to colorectal cancer, AI-driven discovery and protein degradation, the MAPK and cGAS-STING pathways and the idea of a virtual cancer cell. Whether AI-discovered candidates succeed in the clinic at a higher rate than conventional ones is the question the company exists to test.
Connected
20Similar pages
- CompanyInsilico Medicine
Shares A virtual cancer cell that predicts what a drug will do before you test it, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- IdeaIn silico trials to choose the dose before the first patient
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery, Lab models that fail to predict what happens in patients.
- TechnologyChemistry42 and Pharma.AI (Insilico)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- CompanyIsomorphic Labs
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery, The valley of death between lab and product.
- TechnologyChai-1 / Chai-2
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyESM3 (EvolutionaryScale)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyStructural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI-driven drug & target discovery, PROTACs & molecular glues (targeted protein degradation).
- InstitutionCancer Center at Illinois
Shares AI-driven drug & target discovery, Lab models that fail to predict what happens in patients, The valley of death between lab and product.
cancers
fronts
technologies
targets
companies
pathways
trials
roadmaps
ideas
bottlenecks
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
recursion.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Merge worktree-agent-a92b346da6e5b3a8a (orphan trials con… · diff · file · history
Sourced, not expert-reviewed